FDA pauses Orexigen drug approval

June 11, 2014 8:09 PM

15 0

FDA pauses Orexigen drug approval

Vivus and Arena pharmaceuticals will remain the new prescription weightloss drugs for a little longer—the FDA said it wants three more months to review Orexigen Pharmaceutical's weight-loss candidate Contrave, aka NB32. This is the second time the regulator has hit pause, the first time being in 2011 when it rejected the drug.

“We're disappointed that we could not conclude the review by our June 11 PDUFA date...I'm confident we can get the job done,” President and CEO Michael Narachi said during a morning conference call.

Read more

To category page